In Vivo Autoimmune CAR-T Race Grows as Two RNA Startups Enter the Clinic

Why It Matters

In‑vivo CAR‑T could dramatically lower costs and expand access to cell‑based immunotherapies for chronic autoimmune disorders, reshaping a market projected to exceed $30 billion.

Key Takeaways

• Immorna treated systemic sclerosis patient with in‑vivo CAR‑T therapy
• GeneCure began Phase 1 trial for lupus using RNA‑delivered CAR‑T
• In‑vivo approach bypasses costly ex‑vivo cell manufacturing
• Early data show peripheral B‑cell reduction without severe toxicity
• Success could accelerate broader adoption of cell‑free immunotherapies

Pulse Analysis

The emergence of in‑vivo CAR‑T represents a paradigm shift in cellular immunotherapy. Traditional CAR‑T requires extracting a patient’s T cells, engineering them ex‑vivo, and reinfusing the modified cells—a process that can cost hundreds of thousands of dollars per treatment and demand specialized facilities. By delivering messenger RNA encoding the chimeric antigen receptor directly into the bloodstream, RNA‑based platforms aim to program T cells inside the patient’s body, offering a faster, potentially cheaper, and more scalable solution. This technology is especially attractive for chronic autoimmune diseases, where repeated dosing may be necessary, and the logistical burden of ex‑vivo manufacturing has limited broader adoption.

Immorna’s recent case in a systemic sclerosis patient provides the first real‑world glimpse of this approach. The therapy induced a measurable drop in peripheral B‑cell counts, a key driver of the disease, while patients reported no grade‑3 or higher adverse events. Although the data are preliminary and derived from a single subject, the outcome suggests that transient CAR‑T expression can modulate autoimmunity without provoking the cytokine storms seen in oncology applications. GeneCure’s parallel Phase 1 trial in lupus patients will test whether these early signals hold across different autoimmune phenotypes, adding critical comparative data to the field.

The race to commercialize in‑vivo CAR‑T is heating up, with venture capital flowing into RNA delivery platforms and big pharma scouting partnerships. If the ongoing trials confirm safety and efficacy, the market could see a wave of cell‑free immunotherapies that challenge both traditional biologics and ex‑vivo CAR‑T products. Regulators will need to adapt oversight frameworks for transient gene‑editing agents, but the potential to treat millions of autoimmune patients at lower cost positions in‑vivo CAR‑T as a transformative advance in precision medicine.